

Cervical cancer - Pipeline Insight, 2021

<https://marketpublishers.com/r/C88E57AB25A2EN.html>

Date: July 2021

Pages: 60

Price: US\$ 2,500.00 (Single User License)

ID: C88E57AB25A2EN

Abstracts

This report can be delivered to the clients within 2-3 Business Days

DelveInsight's, "Cervical cancer - Pipeline Insight, 2021," report provides comprehensive insights about 70+ companies and 70+ pipeline drugs in Cervical cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Cervical cancer Understanding

Cervical cancer: Overview

Cervical cancer develops in a woman's cervix (the entrance to the uterus from the vagina). Almost all Cervical cancer cases (99%) are linked to infection with high-risk human papillomaviruses (HPV), an extremely common virus transmitted through sexual contact. Although most infections with HPV resolve spontaneously and cause no symptoms, persistent infection can cause Cervical cancer in women. Cervical cancer is the fourth most common cancer in women. In 2018, an estimated 570 000 women were diagnosed with Cervical cancer worldwide and about 311 000 women died from the disease. Effective primary (HPV vaccination) and secondary prevention approaches (screening for, and treating precancerous lesions) will prevent most Cervical cancer cases. When diagnosed, Cervical cancer is one of the most successfully treatable forms

of cancer, as long as it is detected early and managed effectively. Cancers diagnosed in late stages can also be controlled with appropriate treatment and palliative care.

'Cervical cancer - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Cervical cancer pipeline landscape is provided which includes the disease overview and Cervical cancer treatment guidelines. The assessment part of the report embraces, in depth Cervical cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Cervical cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Cervical cancer R&D. The therapies under development are focused on novel approaches to treat/improve Cervical cancer.

Cervical cancer Emerging Drugs Chapters

This segment of the Cervical cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Cervical cancer Emerging Drugs

Cemiplimab: Regeneron Pharmaceuticals

Cemiplimab (Libtayo) is a fully-human monoclonal antibody targeting the immune checkpoint receptor PD-1 on T-cells. By binding to PD-1, Libtayo has been shown to block cancer cells from using the PD-1 pathway to suppress T-cell activation. Currently, it is in Phase III stage of development to treat Cervical cancer.

AK104: Akesobio

AK104 is a potential next-generation, first-in-class humanized IgG1 tetrameric bi-specific antibody drug candidate that is based on Akeso's proprietary "TETRABODY" technology and simultaneously targets two immune checkpoint molecules: PD-1 and CTLA-4. AK104 is in a tetrameric form, which is designed to bind to PD-1 and CTLA-4 simultaneously to achieve the efficacy of PD-1 and CTLA-4 combination blockade with lower toxicity.

Durvalumab: Celgene

Durvalumab is an investigational human monoclonal antibody directed against programmed death ligand-1 (PD-L1). Signals from PD-L1 help tumours avoid detection by the immune system. Durvalumab blocks these signals, countering the tumour's immune-evading tactics. Durvalumab is being investigated in an extensive clinical trial programme, as monotherapy or in combination in multiple cancer types. Currently, it is in Phase III stage of development to treat Cervical cancer.

Further product details are provided in the report.....

Cervical cancer: Therapeutic Assessment

This segment of the report provides insights about the different Cervical cancer drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Cervical cancer

There are approx. 70+ key companies which are developing the therapies for Cervical cancer. The companies which have their Cervical cancer drug candidates in the most advanced stage, i.e. phase III include, Regeneron Pharmaceuticals.

Phases

DelveInsight's report covers around 70+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Cervical cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

intravenous

Subcutaneous

Topical.

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Cervical cancer: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Cervical cancer therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Cervical cancer drugs.

Cervical cancer Report Insights

Cervical cancer Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Cervical cancer Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Cervical cancer drugs?

How many Cervical cancer drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Cervical cancer?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Cervical cancer therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Cervical cancer and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Regeneron Pharmaceuticals

Akesobio

Celgene

AstraZeneca

ImaginAb Inc

Genexine, Inc.

Merck KGaA

Seagen Inc.

Vaccibody AS

Qilu Pharmaceutical Co., Ltd.

Genor Biopharma Co., Ltd.

Agenus Inc.

Immunitor LLC

Genentech

Guangzhou Gloria Biosciences Co., Ltd.

Lee's Pharmaceutical Limited

BeiGene

Henlix Biotech

Biocad

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Cellid Co., Ltd.

Innovent Biologics

Zeria Pharmaceutical

Advaxis, Inc.

Human Genome Sciences

Hookipa Biotech GmbH

Eli Lilly and Company

SK Bioscience Co., Ltd.

Tesaro, Inc

Iovance Biotherapeutics, Inc.

NETRIS Pharma

Advenchen Laboratories, LLC

Rubius Therapeutics

Repertoire Immune Medicines

Bristol-Myers Squibb

Sotio a.s.

VM Oncology, LLC

Andes Biotechnologies

Transgene

Xencor, Inc.

Exelixis

Ocellaris Pharma, Inc

Fate Therapeutics

Arcus Biosciences, Inc.

MacroGenics

Key Products

Cemiplimab

AK104

Durvalumab

MEDI 0457

89Zr Df IAB 22M2C

GX-188E

M7824

Tisotumab Vedotin

VB10.16

QL1604

GB226

AGEN2034

V3-Cervix

Tiragolumab

GLS-010

ZKAB001

Tislelizumab

HLX10

BCD-100

SG001

BVAC-C

IBI310

Z-100

ADXS11-001

Mapatumumab

HB-201

Gemzar

NBP615

Niraparib

LN-145

NP137

AL3818

RTX-321

RPTR-168

BMS-986340

SO-C101

VMD-928

Andes-1537

TG4001

XmAb®23104

XB002

OC-001

FT 500

AB308

MGD013

Contents

Introduction

Executive Summary

Cervical cancer: Overview

Causes

Mechanism of Action

Signs and Symptoms

Diagnosis

Disease Management

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Late Stage Products (Phase III)

Comparative Analysis

Cemiplimab: Regeneron Pharmaceuticals

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Mid Stage Products (Phase II)

Comparative Analysis

AK104: Akeso Biopharma

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Early Stage Products (Phase I/II)

Comparative Analysis

TG4001: Transgene

Product Description

Research and Development

Product Development Activities
Drug profiles in the detailed report.....
Preclinical and Discovery Stage Products
Comparative Analysis
IMGN 151: ImmunoGen
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report.....

Inactive Products
Comparative Analysis
Cervical cancer Key Companies
Cervical cancer Key Products
Cervical cancer- Unmet Needs
Cervical cancer- Market Drivers and Barriers
Cervical cancer- Future Perspectives and Conclusion
Cervical cancer Analyst Views
Cervical cancer Key Companies
Appendix

List Of Tables

LIST OF TABLES

Table 1 Total Products for Cervical cancer
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

Figure 1 Total Products for Cervical cancer

Figure 2 Late Stage Products

Figure 3 Mid Stage Products

Figure 4 Early Stage Products

Figure 5 Preclinical and Discovery Stage Products

Figure 6 Assessment by Product Type

Figure 7 Assessment by Stage and Product Type

Figure 8 Assessment by Route of Administration

Figure 9 Assessment by Stage and Route of Administration

Figure 10 Assessment by Molecule Type

Figure 11 Assessment by Stage and Molecule Type

Figure 12 Inactive Products

I would like to order

Product name: Cervical cancer - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/C88E57AB25A2EN.html>

Price: US\$ 2,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C88E57AB25A2EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970